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The animal model of feline immunodeficiency virus (FIV) infection of cats was used to dissect the pathogenic role of microglia within the first
6 months of infection. Applying real-time PCR, microglia-associated FIV replication was first detectable at 14 days past inoculation (dpi) and
remained at elevated levels throughout the whole observation period. In contrast, FIV RNA levels within paired serum samples declined again
after an initial peak between 14 dpi and 28 dpi. Concomitant with the onset of viral reproduction, microglia transiently upregulated expression of
MHC class I and class II molecules. Virus-induced microglial activation was followed by a mild infiltration of peripheral leukocytes into the CNS
parenchyma. The presented data suggest that microglia is infected by FIV very early after peripheral entry of the virus. Virus replicating microglia
withstands eradication by brain-infiltrating leukocytes resulting in formation of a brain-resident virus reservoir, which probably cannot be cleared
by peripheral chemotherapy.
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Even though it is well established that HIV-1 enters the CNS
shortly after peripheral infection, little is known about the early
pathogenic events within the HIV-affected brain tissue.
Postmortem examinations of asymptomatic HIV patients dying
from unnatural causes, however, suggest neuropathological
alterations in CNS parenchyma already at the pre-AIDS stage
(Gosztonyi et al., 1993; Gray et al., 1992). Moreover, a
growing number of acutely infected HIV+ individuals suffer
from subtle neurological impairments termed minor cognitive/
motor disorder (Ellis et al., 1997a; Goodkin et al., 1997; Saykin
et al., 1991). These findings support the hypothesis that
primary central nervous system HIV infection will provoke
pathological processes eventually leading to severe HIV-
associated dementia (HAD) at late-stage disease that remains0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.08.014
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Mannheim, Germany.an important AIDS-defining illness (Sacktor et al., 2002). A
more complete understanding of early HIV-induced neuro-
pathogenesis could therefore help to design therapeutic
strategies to prevent and treat this component of HIV disease.
In this context, CNS viral load is of particular interest since
it is hypothesized to correlate with onset and progression of
identifiable neurological symptoms (Gray et al., 1996; Wiley
and Achim, 1994). To find such a relationship, a number of
studies have been launched in the past, but the results thereof
are rather controversial. Whereas several groups reported a
positive correlation between viral RNA levels in cerebrospinal
fluid (CSF) and brain tissue to patients’ symptomatology (Brew
et al., 1997; Ellis et al., 1997b; McArthur et al., 1997; Wiley
et al., 1998), others did not (Chiodi et al., 1992; Conrad et al.,
1995). The reasons for these discordant findings may be
manifold. On the one hand, samples used for RNA quantifi-
cation were either derived postmortem or from end-stage
diseased patients, when integrity of the blood–brain barrier
(BBB) might be significantly disturbed (Persidsky et al., 2000;
Power et al., 1993), allowing unlimited access of blood-borne
virus to the CNS. On the other hand, because of practical5) 162 – 170
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RNA levels in CSF specimen that may not accurately reflect
viral load in brain parenchyma since CSF-associated virus
might be derived from several sources including choroid
plexus, meninges, parenchyma or infiltrating leukocytes. Yet,
to study neurologic disease, viral load within brain parenchy-
mal tissue will be probably more relevant. Especially, the
number and distribution of infected microglial cells represent-
ing the main viral targets in the CNS (Cosenza et al., 2002) at
different stages of infection might be a good predictor for
disease progression.
Due to obvious reasons, microglial virus burden cannot be
appropriately examined in human beings. Usually, accessibility
of brain biopsies is restricted and, if available, they represent
only small discrete regions of brain tissue so that the
information provided is unsatisfactory. Therefore, comprehen-
sive studies of lentiviral CNS infection can be exclusively
performed in animal models. Among the latter, infection of
domestic cats with the feline immunodeficiency virus has
gained increasing attention over the last decade since FIV-
infected animals develop a similar immunodeficiency syn-
drome compared to HIV-affected people (Willett et al., 1997).
As HIV, FIV enters the brain very early past peripheral
inoculation (Boche et al., 1996) to establish a persistent
infection of brain endothelial cells (Steffan et al., 1994),
astrocytes and preferentially microglial cells (Dow et al., 1992;
Hein et al., 2000). During the asymptomatic phase of the
infection, number of productively FIV-infected microglial cells
is usually low (Hein et al., 2000) similar to what is seen in HIV-
affected brain (Nuovo et al., 1994). In situ PCR and RT in situ
PCR analyses, however, revealed that the total number of
virally infected microglia might be considerably higher (Nuovo
et al., 1994).
To get a more detailed knowledge of the dynamics of
microglial viral burden during acute lentiviral CNS infection,
we investigated viral RNA levels of feline brain-resident
microglia during the first 6 months of FIV infection and
correlated them to serum RNA of the same animals. Presented
data suggest that FIV enters the microglial population very
early after peripheral inoculation and replicates over the whole
phase of acute infection. Viral RNA synthesis is accompanied
by microglial activation followed by infiltration of peripheral
leukocytes into the brain parenchyma. Since even in the face of
inflammatory processes microglial FIV burden remains elevat-
ed, it seems likely that local immune responses are ineffective
in eliminating virus from the tissue so that an important viral
reservoir will be established.
Results
FIV load of microglia and serum
Previous papers of our group (Hein et al., 2000, 2003) have
revealed feline microglial cells to be FIV-infected and to select
for distinct viral variants very shortly after peripheral inocu-
lation. From these data, it is reasonable to assume that lentiviral
replication takes place within microglia already during acuteCNS infection. Up to date, however, nothing is known about
the dynamics of this early viral reproduction. The present study
was therefore designed to quantify FIV loads of the brain-
resident macrophage population and to correlate them to viral
concentrations of paired serum samples over the first 6 months
of infection. A total of 16 animals were intravenously
inoculated with the FIV isolates Wo or Womic and analyzed
14, 28, 92 and 183 days later. Leukocytes were extracted from
brain tissue by percoll gradient centrifugation and subjected to
three-color flow cytometry. The proportion of microglial cells
was determined by quantifying CD45low expressing cells that
also stained positive for CD18 and MHC antigens. In mean,
2.13  107 T 2.63  106 hematopoietic cells per CNS could be
isolated of which more than 90% were of the microglial
phenotype (Fig. 1).
Although a strong correlation between brain FIV load and
severity of neurological disease has been postulated (Boche et
al., 1996), viral burden of individual CNS cell populations has
not yet been studied. Therefore, we aimed to analyze viral load
of microglia and to compare it with FIV titers of matched
serum samples. To do so, a modified real-time RT-PCR method
that has recently been used to quantify FIV RNA in clinical
specimen (Ryan et al., 2003) was applied. As demonstrated in
Fig. 2, viral replication was detectable within the microglial
population already at 14 dpi (Fig. 2). Interestingly, no
correlation between viral load in microglia and serum from
single cats could be detected, that is, high serum levels were
not always accompanied by high virus RNA burdens in the
microglial cell fraction. Following acute infection, average
viral titers remained at constant levels, even though concentra-
tions of FIV RNA were quite variable between individual
animals. FIV replication in paired serum samples displayed a
similar kinetics but contrarily to microglial specimen declined
again at 183 dpi (Fig. 2). These data support the idea that FIV
invades the brain shortly after peripheral entry of the virus to
establish a persistent infection of the microglial cell fraction.
FIV infection leads to microglial activation
Activated microglia is a prominent feature of central nervous
HIV infection. It is believed that the degree of microglial
activation correlates with neuropathology (Williams and
Hickey, 2002). Similarly, diffuse signs of activation have been
reported within FIV-infected brain tissue, even though these
could not be attributed to a distinct cell population (Johnston et
al., 2002). Therefore, we aimed to analyze if microglia may be
activated following FIV invasion of brain parenchyma. As
read-out system, intensity of microglial MHC expression was
cytofluorographically assessed ex vivo. Relative to uninfected
animals, microglia from infected cats temporarily displayed
upregulation of both MHC class I (Fig. 3) and MHC class II
molecules, reaching maximal levels as early as 14 dpi to
gradually decline to the baseline niveau at 183 dpi (Fig. 4). This
phenomenon was more pronounced regarding MHC class I
since in comparison fluorescence values of MHC class II
exhibited higher variability. As a consequence, no statistically
significant difference (P > 0.05) in the amount of microglial
Fig. 2. Viral loads of microglia and sera from FIV-infected animals. At
different time points past infection (dpi), total RNA was extracted from 3 to
5 microglial (upper graphics) and paired serum (lower graphics) samples
each before being reverse transcribed and amplified by FIV gag specific
real-time PCR. Same symbols represent FIV RNA copy numbers of
individual animals. The asterisk indicates a statistically significant difference
of P < 0.05. Microglia and serum specimens from uninfected animals were
consistently negative.
Fig. 1. Representative FACScan analysis of brain cells isolated from an FIV-infected cat. Immediately after extraction, cells were triple-labeled either with isotype-
matched control antibodies (A, B) or mabs specific for CD45, MHC class II and CD18 (C, D) and subjected to flow cytometry. Numbers in the upper right quadrants
specify total amount of double-positive cells, while boxes highlight percentage of brain-infiltrating leukocytes (C, D).
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animals at 14 dpi. Nevertheless, FIV infection seems to enhance
MHC II expression of microglia even at that early time point
past infection as quantity of cell surface MHC II antigens
substantially decreased from 14 to 183 dpi (P < 0.05) (Fig. 4).
These data suggest that FIV invasion of the brain is
immediately followed by microglial activation.Fig. 3. Representative cytofluorographical analysis of MHC class I antigen
expression on microglial cells during acute central nervous FIV infection.
Following extraction from brain parenchyma at the time points indicated
(14, 183 dpi), microglia was immunostained by means of a mab specific for
MHC class I and an isotype-matched control antibody (IgG, dotted line),
respectively, and subjected to flow cytometry. U = uninfected animal.
Fig. 5. Number of CD45high cells within the feline CNS at different time points
past FIV infection. Following extraction from the brain, amount of CD45high
cells was cytofluorographically determined and plotted versus days past
infection (dpi). Each symbol represents the average number of cells isolated
from the CNS of 3 to 5 animals. Vertical bars indicate the standard deviation.
The solid line represents the mean of CD45high cells isolated from the brain of 4
uninfected animals (dotted lines mark the standard deviation). Asterisks specify
statistically significant differences with respect to uninfected animals (*P <
0.05; **P < 0.01).
Fig. 4. MHC antigen expression on acutely FIV-infected microglia. At 14, 28,
92 and 183 dpi, microglial cells were isolated from the brain of FIV-infected
cats and analyzed for MHC class I (upper diagram) and MHC class II (lower
diagram) antigen expression by means of flow cytometry. Intensity of MHC
expression was determined from the mean fluorescence intensity values
calculated by the CellQuest software. Data represent the means T SD of 3 to
5 independent experiments. Note different scales of y axes. Vertical bars
indicate the standard deviation. The solid line represents the mean fluorescence
intensity calculated from microglial cells of 4 uninfected animals (dotted lines
mark the standard deviation). Where indicated by an asterisk, the difference
between uninfected animals and the sample group or between sample groups
was statistically significant (P < 0.05). MFI, mean fluorescence intensity.
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Since activated microglia is able to release increased levels of
proinflammatory cytokines (Suzumura, 2002), it seemed likely
that elevated numbers of hematopoietic cells entered the acutely
infected CNS. To investigate kinetics of white blood cell
infiltration, the quantity of CD45high expressing cells within
the brain isolated leukocyte fraction was determined by flow
cytometry. Significant differences (P < 0.05) in the amount of
brain-associated CD45high cells between infected animals and
untreated controls could not be detected before 28 dpi (Fig. 5),
i.e., 14 days after FIV-infected microglia displayed maximal
signs of activation. This suggests that lentiviral infection of
microglia promotes its activation that in turn leads to enhanced
secretion of chemoattractants. Interestingly, number of CNS
invading leukocytes remained at heightened levels through 183
dpi, likely indicating an ongoing antiviral immune response.
Discussion
Despite nearly 2 decades of extensive research, etiology of
HIV-associated CNS disease remains far away from beingcompletely understood. Although numerous parameters have
been investigated, solid correlations between lentiviral induced
neuropathology and neurosymptomatology have not yet been
identified. Definition of absolute predictors or markers of HIV-
related brain dysfunctions, however, would facilitate not only
recognition of individuals at risk but also the development of
effective treatment strategies. In this context, type and
distribution of infected cells as well as dynamics of viral
replication within the CNS are of special interest since similar
to peripheral tissues local viral load might influence organ-
specific functions. In fact, virtually all AIDS patients with
advanced immunodeficiency and marked neurological compli-
cations have high levels of virus in the brain (Wiley and
Achim, 1994).
In contrast, little is known about CNS-associated lentiviral
burden early in infection and to what extent it affects the
subsequent evolution of neurological complications. Using the
animal model of FIV infection of cats, we present here for the
first time data about the ex vivo kinetics of viral replication in
the majority of brain-resident ramified microglia within the first
6 month past peripheral entry of a lentivirus. Moreover,
phenotypic changes within this cell compartment associated
with lentiviral infection were recorded. Whereas accumulated
data from HIV infection or the SIV model mainly report on the
clinical stage of CNS infection with little or no effort to
distinguish between brain-infiltrating macrophages and resi-
dent microglia, we used flow cytometry to unequivocally
identify brain-isolated cells as microglia by virtue of their low
CD45 expression. We feel that this is an important point to
stress because to date it is clear that the perivascular
macrophage/microglia compartment can clearly be separated
from the tissue-based ramified microglia (Albright et al., 2000;
Becher and Antel, 1996). Whereas lentiviral load of the
perivascular compartment is fueled by a frequent exchange of
monocytes from the blood (Fischer-Smith et al., 2001),
ramified microglia is a long living cell population with little
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therapy may lower the perivascular viral load in the CNS but
most likely does not affect the viral burden in ramified
microglia. From that point of view, ramified microglia may
constitute a unique compartment for the adaptation of
lentiviruses to the brain, especially when persistently infected
for many years in the absence of clinical signs of infection.
Our data indicate that already during primary viremia FIV
enters the CNS to productively infect the ramified microglial
population. Elevated levels of microglia-associated FIV RNA,
however, were unexpected since ex vivo analysis during early
central nervous FIV infection disclosed a rather low amount of
viral p24 antigen positive microglia (Hein et al., 2000). One
might therefore assume that either amount of virally affected
microglia has hitherto been underestimated or FIV replication
rates must be extensive within individual infected cells.
Interestingly, microglial FIV RNA concentrations remain at
elevated levels until 6 months past infection, while serum loads
decline after an initial peak during the first 28 dpi. At first
glance, these results contrast previous findings in SIV and FIV
infection, suggesting that after CNS invasion virus RNA
burden is reduced again even though the virus persists (Boche
et al., 1996; Clements et al., 2002; Poli et al., 1999; Ryan et al.,
2003). These conflicting data might be attributed to the facts
that the latter studies not only used other virus isolates but also
different experimental systems or crude brain homogenates to
quantify viral loads. On the other side, one might argue that
number of animals investigated in this study is too low to allow
statistically relevant statements on differences between brain
and serum FIV loads. But, even if there would be no
differences, our data clearly indicate steady viral reproduction
in FIV-infected microglial cells.
In face of an inflammatory response, ongoing virus
replication is somewhat surprising and implies that infiltrating
leukocytes are either not virus-specific or not able to inhibit
viral reproduction. In fact, in this study, the extraordinary mild
inflammatory reaction prevented a statistically reliable analysis
of composition and function of brain-infiltrating cells. Thus,
inflammatory cells were solely defined by high expression of
the CD45 antigen. Since the animals were not perfused before
extraction of inflammatory cells, one could argue that there is a
considerable contamination of CD45high cells by leukocytes
coming from brain capillaries. For two reasons, we think that
this is not the case. (1) Brain capillaries are very well separated
from brain-extracted cells during percoll gradient centrifuga-
tion. (2) In case of contamination, one would expect far more
CD45high cells with a comparable amount of these cells at all
times past infection. However, an increase of CD45high cells is
noticeable over the time of infection.
Even though activated microglia may also transform to
CD45high expressing cells, microglial contamination of the
CD45high leukocyte population is unlikely since, at 14 dpi,
when activation of microglia reaches its maximum, only a few
CD45high leukocytes can be detected in CNS tissue. Moreover,
in our experience, even activated microglia never reach a level
of CD45 expression, which is seen on peripheral leukocytes
(Sedgwick et al., 1991).On the other hand, there is a possibility that monocytes and
granulocytes, which are CD45high as well, and not lymphocytes
are the major cell types invading the CNS during acute FIV
infection. Myeloid cells, however, are not the traditional
effector cells in antiviral immune reactions and therefore are
not able to downregulate viral replication within FIV-infected
microglial cells.
Another possible explanation for continuous microglial FIV
RNA synthesis is provided from data derived from an
accelerated SIV model. Here, it has been shown that viral
CNS invasion is followed by infiltration of CD4+-, CD8+-T
lymphocytes and NK cells (Mankowski et al., 2002). As a
consequence, viral RNA burden in brain tissue is transiently
reduced, but, late in infection, viral replication might be
reactivated, although number of parenchymal NK cells and
CD8+-T lymphocytes coincidently increases. Obviously, these
cells are functionally inactive or do not have the capacity to
control production of viral progenies. This idea is supported by
recent observations that NK cells from SIV infected monkeys
loose their lytic activity with progression of the disease (Shieh
et al., 2001). In HIV infection, it has been demonstrated that
CD8+-T cells from infected patients exhibit transformation
from a Th1- to a Th2-like phenotype concomitant with reduced
cytolytic function (Appay et al., 2000; Maggi et al., 1994).
Furthermore, HIV-infected monocytes/macrophages down-
regulate costimulatory molecules like B7 and acquire cyto-
toxic activity towards contacting lymphocytes (Dudhane et al.,
1996). The latter, in turn, may stimulate viral replication in
microglial cells by soluble factors (Copeland et al., 1998) and
receptor–ligand interactions, respectively (Hein et al., 2001).
It is therefore conceivable that inflammatory processes that
are regularly detectable at all stages of lentiviral-induced CNS
disease (Gray et al., 1996) may even enhance local viral load
instead of eradicating virus from the tissue. Indeed, using the
model of Friend murine leukemia virus (F-MuLV) infection of
rats, our group recently could show that adaptive transfer of
virus-specific immune cells reduced retroviral titers in
peripheral organs of infected recipients but not CNS-associ-
ated virus levels despite an influx of activated T- and NK cells
(Hein et al., 1995). Obviously, most of infected brain cells
escaped the immunological attack, thus forming an important
source of newly synthesized virus. Continuous retroviral
replication eventually may give rise to distinct neurotropic
and/or neurovirulent isolates how it was reported in HIV, SIV
and FIV infection (Hein et al., 2003; Power et al., 1998;
Ryzhova et al., 2002). These brain-adapted viruses may
efficiently distribute throughout the whole CNS parenchyma
so that higher viral loads will be achieved at later stages of the
disease leading to increased neuronal injury.
Another prominent finding of the present study is the
transient upregulation of MHC molecules on microglial cells
isolated from FIV-infected animals. Similarly, enhanced MHC
expression can be detected on acutely SIV (Chakrabarti et al.,
1991; Clements et al., 2002)- and HIV (Gray et al., 1991)-
infected microglia. This microglial activation, in turn, might be
associated with increased secretion of potentially neurotoxic
substances including viral proteins, quinolinic acid, arachido-
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2001). Besides, augmented levels of various cytokines and
chemokines (Kelder et al., 1998; Poli et al., 1999) may be
released that may not only contribute to neuropathogenesis but
also cause inflammation and opening of the BBB (Gray et al.,
1996; Mankowski et al., 2002). BBB alterations, however,
might facilitate not only viral brain access but also penetration
of blood-borne toxic products other than viral components. If
so, the latter would represent an alternative pathway by which
HIV-induced dementia could occur without the necessity of the
virus to invade the tissue. Whatever the pathological con-
sequences of early microglial activation may be, their
resolution is a formidable task since they seem to predispose
HIV-infected patients to develop severe CNS symptomatology
(Tomlinson et al., 1999).
Taken together, the present study provides further evidence
that FIV gets access to the brain very shortly after peripheral
entry of the virus to reside within the microglia. Its infection is
accompanied by activation and immediate production of
constant levels of viral progenies even in the presence of an
inflammatory response. In contrast, after an initial peak, serum-
associated FIV replication is suppressed again, indicating
different efficiencies of brain-located and peripheral immune
reactions. As a consequence, virus might not be eliminated
from the microglial population, thereby establishing an
important viral reservoir. Viral eradication from the microglia
will therefore be of key importance in the development of
antiviral drugs capable of preventing and treating of lentiviral-
induced CNS disease.
Materials and methods
Animals
Cats (21 male, 6 months old, strain Ico:Fec Eur, Tif) were
obtained from IFFA Cre´do (Lyon, France) and maintained
under specific-pathogen-free (SPF) conditions. Seventeen
animals were intravenously inoculated with cell-free tissue
culture supernatant (TCS) containing 5000 cat infectious doses
(CID)50 of FIV strains Wo (7 cats) and Womic (10 cats),
respectively. Four cats were left untreated as controls. Three to
five cats each were sacrificed at 14, 28, 92 and 183 dpi,
respectively, and immediately necropsied. All animal experi-
mental procedures were performed according to local rules for
care and use of laboratory animals.
Viruses
Strain FIV Wo (kind gift of A. Moraillon, E´cole Ve´te´rinaire,
Maison d’Alfort, France) was originally obtained from a cat at
end-stage disease by coculture of its blood-derived leukocytes
with peripheral blood mononuclear cells (PBMC) from
uninfected animals. Strain FIV Womic was recovered from
microglia of an experimentally FIV Wo-infected animal by
culturing together with phytohemagglutinin (PHA)-activated
lymphocyte blasts. Viral stocks were prepared as previously
described (Hein et al., 2000) and stored in aliquots at 80 -C.Isolation of microglial cells
Microglial cells were isolated from the CNS using a
previously published protocol (Hein et al., 2000). Briefly, total
CNS tissue was aseptically removed and freed from meninges.
Subsequently, brain material was mechanically disrupted
before being digested with a mixture of DNAse I (Roche,
Mannheim, Germany) and collagenase (Serva, Heidelberg,
Germany). The resulting tissue homogenate was transferred to
a percoll gradient prepared of two layers of different density
and centrifuged at 1250  g for 20 min. Following removal of
myelin, cells were overlayered onto a second multilayer
gradient and centrifuged again using the same conditions as
for the first gradient. Finally, microglial cells could be
recovered at high purity from the 1072 g/cm3 interphase.
Flow cytometry
Brain-extracted leukocytes were immunostained using the
following monoclonal antibodies (mabs) and polyclonal
immunoglobulin (Ig)G fractions: anti-human CD18 (clone
MHM23, mouse IgG1; fluorescein isothiocyanate (FITC)
conjugate; Dako, Glostrup, Denmark) cross-reactive with its
feline homologue, CD45 (clone 25-2C, mouse IgM; VMRD,
Pullman, USA) as well as anti sheep MHC class I (clone
VPM19, mouse IgG1; Acris, Hiddenhausen, Germany), also
recognizing the corresponding feline antigen, and MHC class II
(clone vpg 3, mouse IgG1; Acris, Hiddenhausen, Germany).
Isotype-matched control antibodies (clone 15H6, mouse IgG1;
clone 11E10, mouse IgM; SBA, Birmingham, USA) were used
to control for background staining. Primary mabs were detected
by R-phycoerythrin (PE)- or biotin-conjugated F(ab’)2 frag-
ments of goat anti-mouse IgG and IgM heavy chains (Dianova,
Hamburg, Germany), respectively. To visualize biotinylated
secondary antibodies, streptavidin–RED670 (GibcoBRL,
Eggenstein, Germany) was used. Cells were triple-labeled with
mabs by resuspending in undiluted tissue culture supernatant
(VPM19, vpg 3) and anti-feline CD45 (10 Ag/ml) in a final
volume of 50 Al containing 10% heat-inactivated normal cat
serum to block nonspecific mab binding. Mabs were incubated
for 20 min at 4 -C and washed before adding a mixture of heavy
chain specific R-PE- and biotin-conjugated goat anti-mouse
IgG and IgM at 10 Ag/ml including 10% normal goat serum
and incubating for another 20 min on ice. Cells were washed,
and conjugate-associated free binding sites were saturated by
20% normal mouse serum (10 min, 4 -C). Subsequently,
CD18 mab (10 Ag/ml) was added together with streptavidin–
RED670 (5 Ag/ml) and incubated for 20 min at 4 -C. Finally,
washed cells were subjected to flow cytometry, and 1  104
live-gated events were assessed on a FACScan (Becton
Dickinson, Heidelberg, Germany) using the CellQuest soft-
ware package Version 1.0.
RT-PCR
Total RNA from paired serum and microglial samples was
extracted using the QIAamp MinElute Virus Spin Kit and
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respectively, following the manufacturer’s instructions. To
avoid amplification of contaminating DNA sequences,
isolated nucleic acids were treated by RNase-free DNase I
(15 min, 37 -C). Subsequently, 30 ng of RNA (determined
by photometry at 260/280 nm; Genequant, Amersham
Biosciences, Freiburg, Germany) was reverse transcribed by
means of the First Strand cDNA Synthesis Kit for RT-PCR
from Roche Diagnostics (Mannheim, Germany) and 20 pmol
of the FIV gag specific primer 1437r (5V-TATGGCGGC-
CAATTTT CCT-3V; Klein et al., 2001). Amplification of FIV
gene sequences was performed applying a commercially
available kit (LightCycler FastStart DNA master SYBR
Green I; Roche Diagnostics, Mannheim, Germany), 2.5
mM MgCl2, 8 Al cDNA and 10 pmol each of the primers
1360f (5V-GCAGAAGCAAGATTTGCACCA-3V; Klein et al.,
2001) and 1437r, respectively, in a final volume of 20 Al.
PCR conditions were as follows: denaturing for 10 min at 95
-C followed by 50 cycles of 95 -C for 15 s, 60 -C for 5 s
and 72 -C for 4 s. Amplification, data acquisition and
analysis were performed on a LightCycler instrument (Roche
Diagnostics, Mannheim, Germany). To verify multiplication
of single amplicons, PCR products were routinely checked
by melting point analysis as well as electrophoresis through
2% agarose gels containing 0.5 Ag/ml ethidium bromide.
RNA quantification standards
A 452 base pair fragment of the FIV gag region was
amplified using DNA from chronically infected FL-4 cells
(Yamamoto et al., 1991) as template and the previously
published primers FIVgag1261 (5V-CAGAATATGATCGCA-
CACATC-3V) and FIVgag1693 (5V-AAGAGCTTCTGCCAA-
GAGTT-3V) (Hein et al., 2000) and cloned into the pCR\II-
TOPO vector (Invitrogen, Carlsbad, USA) according to the
manufacturer’s recommendations. Recombinant plasmids
were selected and sequenced by automated dideoxy sequenc-
ing on an ABI 3700 capillary sequencer (Applied Biosystems,
Foster City, USA). One plasmid (pCR\II-TOPO-FIVgag)
containing an unaltered copy of the original FIV gag gene
sequence was digested with SacI before being used as
template for in vitro transcription applying the SP6/T7
transcription kit from Roche Diagnostics (Mannheim, Ger-
many). Following DNase I treatment to remove plasmid
DNA, RNA copy number was calculated from optical density
at 260 nm. For establishment of standard curves, tenfold
dilution series were prepared in nuclease-free water with 16S
and 23S rRNA (Roche, Mannheim, Germany) as carrier
RNA.
Statistical analysis
Data were expressed as mean and standard deviation (SD).
Differences between the results obtained from multiple groups
were investigated using one-way ANOVA followed by Tukey’s
multiple comparison test. A probability value of P  0.05 was
considered significant.Acknowledgments
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